Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Big 4 Wholesalers’ Operating Margin Sinks to 0.49% on COVID-19, Competition
May 17, 2021
-
BUSINESS 2 Ono Employees Admits Bribery Charges over Onoact Prescriptions
May 17, 2021
-
REGULATORY Japan, Pfizer Agree on 50 Million Extra Vaccine Doses by Sept-End
May 17, 2021
-
BUSINESS FY2020 Sales of 7 Major Japan Drug Makers Slip 2.7% on COVID-19, Price Woes: Tally
May 14, 2021
-
BUSINESS Ono Cuts Opdivo Guidance to 110 Billion Yen for FY2021
May 14, 2021
-
REGULATORY Pharma Groups Want Price Maintenance for Patented Meds, Payer Sees It “Natural” to Rectify Gap: Chuikyo
May 13, 2021
-
REGULATORY Chuikyo OKs Re-Pricing for Tecentriq, Vyndaqel; 3 I/O Peers Challenge Cuts in Vain
May 13, 2021
-
REGULATORY May Listing OK’ed for Darzquro, Pemazyre, Vitrakvi, Kesimpta and More
May 12, 2021
-
REGULATORY Ultomiris Faces 4.3% Price Cut under CEA Scheme
May 12, 2021
-
REGULATORY Tecentriq, 3 I/O Rivals Face Quarterly Re-Pricing; Price Cuts Yet Again for Opdivo, Keytruda
May 11, 2021
-
BUSINESS Takeda Submits Positive Japan Data for Approval-Pending Moderna Vaccine
May 11, 2021
-
BUSINESS Novartis Says Only 3,000 Pollen Allergy Patients Used Xolair This Season, Less than 10% of Re-Pricing Line
May 10, 2021
-
ORGANIZATION JPMA Has “Different View” from US Govt on COVID-19 Vaccine IP Waiver
May 10, 2021
-
BUSINESS Kyoto Startup to Begin Clinical Trial of iPSC-Derived Platelet Agent This Year, Eyes 10 Billion Yen Biz
May 10, 2021
-
BUSINESS Drug Makers’ Female Manager Ratio at 12.5%; Major Gap between Japan, Foreign Players
April 30, 2021
-
REGULATORY MHLW Revokes Approval for 12 Kobayashi Kako Products, Imposes Biz Improvement Order
April 30, 2021
-
BUSINESS Takeda, Eisai, Chemiphar Ran Early Retirement Programs over Past Year: Survey
April 28, 2021
-
BUSINESS Boehringer’s Japan Pharma Sales Rise 3.1% in 2020 on Ofev, Jardiance
April 28, 2021
-
BUSINESS Novartis Offering Voluntary Redundancy for 3rd Consecutive Year, Targets Sales & Medical across Therapeutic Areas
April 27, 2021
-
REGULATORY LDP Team Adopts Proposals to Push Japan-Made COVID-19 Vaccines, Urges Approval with Safety/Immunogenicity Studies
April 27, 2021
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…